MedTrace Logo

Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease

NCT02885857 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2016-09-01

No results posted yet for this study

Summary

Safety and efficacy of long-term application of Shenyankangfu Tablets in Large sample of patients with chronic kidney disease.

Conditions

Interventions

DRUG

Shenyan Kangfu Tablet

Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.

Sponsors & Collaborators

  • Tianjin TongRenTang Group Co., Ltd.

    collaborator UNKNOWN

  • Chen Xiangmei

    lead OTHER

Principal Investigators

  • YongLi Zhan, investigator · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

  • HongTao Yang, investigator · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

  • Meng Liang, investigator · 174th hospital of the People's Liberation Army

  • Lu Ma, investigator · Beidaihe Sanatorium of Beijing Military Mrca

  • LiQun Song, investigator · Heilongjiang University of Chinese Medicine

  • QiaoLing Zhou, investigator · Xiangya Hospital of Central South University

  • Ping Luo, investigator · Second Hospital of Jilin University

  • RongShan Li, investigator · Shanxi provincial peple's hospital

  • XiaoHong Cheng, investigator · Shaanxi Traditional Chinese Medicine Hospital

  • Jie Wu, investigator · Chinese PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885857 on ClinicalTrials.gov